SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Immunomedics, Inc. Reports Final Results From Phase Ib/II Study of Yttrium-90-Labeled Clivatuzumab Tetraxetan and Gemcitabine in Advanced Pancreatic Cancer